NCE-1 Intelligence & Market Opportunity

Ensacove

Ensartinib

Anticancer

Oral Capsules

Ensacove is an oral kinase inhibitor for adults with ALK-positive, locally advanced or metastatic non-small cell lung cancer who haven’t previously received ALK-targeted therapy. It blocks ALK-driven signaling to help control tumor growth and delay disease progression.

Approval Date

18-Dec-24

NCE-1 Date

18-Dec-28

NCE Date

18-Dec-29

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

2028

2029

2030

2031

2032

Molecule profile

Details & specifications

Molecule

Ensartinib

Innovator

XCOVERY HOLDINGS INC

Dosage Form

Oral Capsules

Strength

25 mg and 100 mg

Therapeutic Category

Anticancer

Usage

To treat non-small cell lung cancer

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.